

Mandatory Quality-Related Event Reporting in Canada A Province-Wide Review Over Seven Years (2010-2017)

Adrian Boucher,^{1,2} Certina Ho,^{1,2} Todd A. Boyle,³ James Barker,⁴ Bev Zwicker,⁵ Neil MacKinnon⁶

¹ Institute for Safe Medication Practices Canada, ² Leslie Dan Faculty of Pharmacy, University of Toronto, ³ Gerald Schwartz School of Business, St. Francis Xavier University, ⁴ Rowe School of Business, Dalhousie University, ⁵ Nova Scotia College of Pharmacists, ⁶ James L. Winkle College of Pharmacy, University of Cincinnati



• The Community Pharmacy Incident Reporting (CPhIR) program is designed



-90%

-80%

-70%

-60%

-50%

-40%

-30%

-20%

-10%

• A total of 131,031 QREs were anonymously

- by the Institute for Safe Medication Practices Canada (ISMP Canada), a national medication safety organization. CPhIR contributes to the Canadian Medication Incident Reporting and Prevention System (CMIRPS).
- SafetyNET-Rx is a standardized continuous quality improvement (CQI) program for community pharmacies in Nova Scotia, Canada. It aims to create an open dialogue on quality-related events (QREs) in pharmacies and facilitate shared learning to advance patient and medication safety.
- The aim of this study is to quantify and characterize medication-related QREs anonymously reported to CPhIR by community pharmacies in Nova Scotia over 7 years.

Methods

- A retrospective analysis was conducted on medication-related QREs from Nova Scotia community pharmacies occurring between October 1, 2010 and June 30, 2017.
- Descriptive analysis was performed on all medication-related QREs with respect to outcome, type of incident, discoverer, medication system stages, and medications involved.

FIGURE 1. QRES REPORTED BY OUTCOME reported by 301 community pharmacies in Nova Scotia. Of those, 74.87% (98,097) were medication-related QREs.

- Overall, 82.05% (80,488) of reported medication-related QREs did not reach the patient (i.e. near misses). A small proportion, 0.95% (928), reached the patient and resulted in harm (Figure 1).
- The most common types of QREs were incorrect dose/frequency, incorrect quantity, and incorrect drug (Figure 2).
- Pharmacists discovered the majority of medication-related QREs (75.17%), followed by pharmacy assistants/technicians (10.29%) and patients (9.92%).
- The most frequently reported medication system stage was order entry (58.71%), followed by prescription preparation/ dispensing (29.30%), and prescribing (8.96%).
- The most frequently reported medications were levothyroxine sodium, amoxicillin, and rosuvastatin (Table 1). (Note: It is possible that the likelihood of a medication to be involved in a QRE is correlated with the frequency the medication is dispensed in community pharmacy.)

Death	Severe HARM	Moderate HARM	Mild HARM	No HARM	No Error

FIGURE 2.

QRES REPORTED BY TYPE OF INCIDENT



 Medications with the highest proportion of QREs reported with harm were methadone, risperidone, and warfarin (Table 2).

Conclusions

- Medication-related QREs from community pharmacies differ from other healthcare settings reported in the literature, with respect to outcome, type of incident, discoverer, medication system stages, and medications involved.
- These findings provide direction on how to best focus resources to prevent QREs in community pharmacy.
- Through the analysis of QREs and sharing of findings, practitioners can learn from reported QREs and implement safeguards.
- Creating a culture of patient safety with the support of an anonymous, non-punitive reporting system needs to be encouraged within all areas of pharmacy practice.

TOP 10 MEDICATIONS WITH RESPECT TO THE NUMBER OF REPORTED QRES

TOP 10 MEDICATIONS BY PROPORTION OF QRES REPORTED WITH HARM (MINIMUM OF 10 QREs REPORTED WITH HARM)

Medication	Number of QREs	Medication	Number of QREs	Number of QREs	Proportion of QREs
			Reported with Harm		Reported with Harm
Levothyroxine sodium	2,433 (2.34%)	Methadone	19 (1.79%)	184 (0.18%)	10.33%
Amoxicillin	2,361 (2.27%)	Risperidone	11 (1.03%)	313 (0.30%)	3.51%
Rosuvastatin	1,905 (1.84%)	Warfarin	22 (2.07%)	746 (0.72%)	2.95%
Lorazepam	1,840 (1.77%)	Morphine	16 (1.50%)	568 (0.55%)	2.82%
Hydromorphone	1,826 (1.76%)	Atenolol	14 (1.32%)	544 (0.52%)	2.57%
Metoprolol	1,786 (1.72%)	Citalopram	27 (2.54%)	1,261 (1.21%)	2.14%
Salbutamol	1,745 (1.68%)	Norgestimate and estrogen	10 (0.94%)	528 (0.51%)	1.89%
Metformin	1,568 (1.51%)	Levothyroxine sodium	46 (4.32%)	2,433 (2.34%)	1.89%
Rabeprazole	1,459 (1.41%)	Gliclazide	13 (1.22%)	694 (0.67%)	1.87%
Zopiclone	1,374 (1.32%)	Ramipril	14 (1.32%)	778 (0.75%)	1.80%
Total	103,812**	Total	1,064*	103,812**	_

*Total of all reported medications in QREs with harm (excluding free-form entry of medication name) **Total of all reported medications in QREs (excluding free-form entry of medication name)

The authors would like to acknowledge the support from: The Nova Scotia College of Pharmacists, The Institute for Safe Medication Practices Canada, The SafetyNET-Rx Research Team, The Advanced Pharmacy Practice Experience program and the Enhancing the Student Experience Fund at the Leslie Dan Faculty of Pharmacy, University of Toronto, Dalhousie University

Disclosures: Authors of this poster have the following to disclose concerning possible personal or financial relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation: Adrian Boucher: Nothing to disclose; Certina Ho: Nothing to disclose; Todd A. Boyle: Nothing to disclose; James Barker: Nothing to disclose; Bev Zwicker: Nothing to disclose; Neil MacKinnon: Nothing to disclose.